117 related articles for article (PubMed ID: 37357950)
1. A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Seo S; Keam B; Shin SH; Chae YS; Kim TM; Park LC; Hong SB; Ahn MJ; Kim SB
Int J Cancer; 2023 Oct; 153(8):1501-1511. PubMed ID: 37357950
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Marret G; Isambert N; Rezai K; Gal J; Saada-Bouzid E; Rolland F; Chausson M; Borcoman E; Alt M; Klijanienko J; Vansteene D; Guigay J; Kamal M; Bièche I; Le Tourneau C;
Invest New Drugs; 2021 Dec; 39(6):1641-1648. PubMed ID: 34322775
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
[TBL] [Abstract][Full Text] [Related]
5. Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
Clark JI; Greene JB; Lau Clark A; Dalal JS; Hofmeister CC
Med Oncol; 2013 Mar; 30(1):358. PubMed ID: 23266940
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Machiels JP; Kaminsky MC; Keller U; Brümmendorf TH; Goddemeier T; Forssmann U; Delord JP
Invest New Drugs; 2013 Oct; 31(5):1207-16. PubMed ID: 23397499
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Bowles DW; Senzer N; Hausman D; Peterson S; Vo A; Walker L; Cohen RB; Jimeno A
Invest New Drugs; 2014 Dec; 32(6):1197-203. PubMed ID: 24916771
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
Cleary JM; McRee AJ; Shapiro GI; Tolaney SM; O'Neil BH; Kearns JD; Mathews S; Nering R; MacBeath G; Czibere A; Sharma S; Korn WM
Invest New Drugs; 2017 Feb; 35(1):68-78. PubMed ID: 27853996
[TBL] [Abstract][Full Text] [Related]
12. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Dennis MJ; Sacco AG; Qi Y; Bykowski J; Pittman E; Chen R; Messer K; Cohen EEW; Gold KA
Oral Oncol; 2022 Dec; 135():106219. PubMed ID: 36279618
[TBL] [Abstract][Full Text] [Related]
14. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Vermorken JB; Guigay J; Mesia R; Trigo JM; Keilholz U; Kerber A; Bethe U; Picard M; Brummendorf TH
Br J Cancer; 2011 May; 104(11):1691-6. PubMed ID: 21540865
[TBL] [Abstract][Full Text] [Related]
16. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
Bowles DW; Keysar SB; Eagles JR; Wang G; Glogowska MJ; McDermott JD; Le PN; Gao D; Ray CE; Rochon PJ; Roop DR; Tan AC; Serracino HS; Jimeno A
Oral Oncol; 2016 Feb; 53():74-9. PubMed ID: 26705064
[TBL] [Abstract][Full Text] [Related]
19. Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.
Dillon MT; Grove L; Newbold KL; Shaw H; Brown NF; Mendell J; Chen S; Beckman RA; Jennings A; Ricamara M; Greenberg J; Forster M; Harrington KJ
Clin Cancer Res; 2019 Jan; 25(2):487-495. PubMed ID: 30327312
[TBL] [Abstract][Full Text] [Related]
20. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Reynolds KL; Bedard PL; Lee SH; Lin CC; Tabernero J; Alsina M; Cohen E; Baselga J; Blumenschein G; Graham DM; Garrido-Laguna I; Juric D; Sharma S; Salgia R; Seroutou A; Tian X; Fernandez R; Morozov A; Sheng Q; Ramkumar T; Zubel A; Bang YJ
BMC Cancer; 2017 Sep; 17(1):646. PubMed ID: 28899363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
